{"transactions":[{"id":1007687,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-11-05T21:16:56.000Z","date":"2025-11-03","kind":"grant","planned":false,"acquired":true,"shares":67492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Underlying shares each vested on November 3, 2025."}],"balance_after":67492,"derivative":{"exercise_price":1.15,"exercise_date":"2025-11-03","expiration_date":"2035-11-03","underlying":"Common Stock","underlying_shares":67492},"source":{"system":"sec-edgar","filing":"0000905148-25-003782","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825003782/form4.xml","form_type":"4"}},{"id":1172353,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-15T11:59:22.000Z","date":"2025-04-14","kind":"purchase","planned":false,"acquired":true,"shares":490,"price":0.9985,"value":489.265,"ownership":{"direct":true},"balance_after":73639,"source":{"system":"sec-edgar","filing":"0000905148-25-001215","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825001215/form4.xml","form_type":"4"}},{"id":1174489,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-10T20:29:49.000Z","date":"2025-04-10","kind":"purchase","planned":false,"acquired":true,"shares":1167,"price":0.8572,"value":1000.3524,"ownership":{"direct":true},"balance_after":73149,"source":{"system":"sec-edgar","filing":"0000905148-25-001190","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825001190/form4.xml","form_type":"4"}},{"id":1174488,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-10T20:29:49.000Z","date":"2025-04-09","kind":"purchase","planned":false,"acquired":true,"shares":1136,"price":0.8747,"value":993.6592,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices of $0.8741 through $0.88, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth."}],"balance_after":71982,"source":{"system":"sec-edgar","filing":"0000905148-25-001190","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825001190/form4.xml","form_type":"4"}},{"id":1258178,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":false,"shares":1733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. On February 18, 2025, the reporting person received 1,733 shares of common stock of the issuer in settlement of RSUs, which vested on March 23, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. On February 18, 2025, the reporting person received 1,733 shares of common stock of the issuer in settlement of RSUs, which vested on March 23, 2024."}],"balance_after":1733,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1733},"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1258177,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":false,"shares":770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 770 shares of common stock of the issuer in settlement of RSUs, which vested on September 29, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 770 shares of common stock of the issuer in settlement of RSUs, which vested on September 29, 2024."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":770},"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1258176,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":false,"shares":2311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 2,311 shares of common stock of the issuer in settlement of RSUs, which vested on July 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 2,311 shares of common stock of the issuer in settlement of RSUs, which vested on July 1, 2024."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2311},"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1258175,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Performance Stock Units","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":false,"shares":3467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 3,467 shares of common stock of the issuer in settlement of PSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 3,467 shares of common stock of the issuer in settlement of PSUs."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3467},"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1258174,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":1733,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":70846,"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1258173,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":770,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":69113,"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1258172,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":2311,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":68343,"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1258171,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":3467,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":66032,"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1719676,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-12-07T21:51:56.000Z","date":"2023-12-05","kind":"exercise","planned":false,"acquired":false,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on June 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on June 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-23-057725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123057725/doc4.xml","form_type":"4"}},{"id":1719675,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-07T21:51:56.000Z","date":"2023-12-07","kind":"sale","planned":false,"acquired":false,"shares":4550,"price":2.239,"value":10187.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $2.15 through $2.31, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth."}],"balance_after":62565,"source":{"system":"sec-edgar","filing":"0001209191-23-057725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123057725/doc4.xml","form_type":"4"}},{"id":1719674,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-07T21:51:56.000Z","date":"2023-12-06","kind":"sale","planned":false,"acquired":false,"shares":14500,"price":2.3101,"value":33496.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $2.22 through $2.48, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth."}],"balance_after":67115,"source":{"system":"sec-edgar","filing":"0001209191-23-057725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123057725/doc4.xml","form_type":"4"}},{"id":1719673,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-07T21:51:56.000Z","date":"2023-12-05","kind":"exercise","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":81615,"source":{"system":"sec-edgar","filing":"0001209191-23-057725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123057725/doc4.xml","form_type":"4"}},{"id":1905374,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-05-04T20:38:07.000Z","date":"2023-04-26","kind":"exercise","planned":false,"acquired":false,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."}],"balance_after":3466,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1734},"source":{"system":"sec-edgar","filing":"0001209191-23-027361","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123027361/doc4a.xml","form_type":"4/A","original_submission_date":"2023-04-14"}},{"id":1905373,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-05-04T20:38:07.000Z","date":"2023-04-26","kind":"exercise","planned":false,"acquired":false,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1010},"source":{"system":"sec-edgar","filing":"0001209191-23-027361","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123027361/doc4a.xml","form_type":"4/A","original_submission_date":"2023-04-14"}},{"id":1905372,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-04T20:38:07.000Z","date":"2023-04-26","kind":"sale","planned":false,"acquired":false,"shares":692,"price":3.6381,"value":2517.5652,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."}],"balance_after":11615,"source":{"system":"sec-edgar","filing":"0001209191-23-027361","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123027361/doc4a.xml","form_type":"4/A","original_submission_date":"2023-04-14"}},{"id":1905371,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-04T20:38:07.000Z","date":"2023-04-26","kind":"exercise","planned":false,"acquired":true,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The beneficially owned shares have been adjusted as the restricted stock units previously reported as settled on April 12, 2023 were not settled on that date.  The restricted stock units settled on April 26, 2023."}],"balance_after":12307,"source":{"system":"sec-edgar","filing":"0001209191-23-027361","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123027361/doc4a.xml","form_type":"4/A","original_submission_date":"2023-04-14"}},{"id":1905370,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-04T20:38:07.000Z","date":"2023-04-26","kind":"exercise","planned":false,"acquired":true,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The beneficially owned shares have been adjusted as the restricted stock units previously reported as settled on April 12, 2023 were not settled on that date.  The restricted stock units settled on April 26, 2023."}],"balance_after":14041,"source":{"system":"sec-edgar","filing":"0001209191-23-027361","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123027361/doc4a.xml","form_type":"4/A","original_submission_date":"2023-04-14"}},{"id":1920112,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance Stock Units","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The vested performance stock units (PSUs) represent PSUs deemed by the compensation committee to be vested at target due to the change in the issuer's business model. The remaining PSUs vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023.  One quarter of the initial PSUs were forfeited based on the failure of the issuer to achieve certain EBITDA milestones for the year ended December 31, 2021.  Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The vested performance stock units (PSUs) represent PSUs deemed by the compensation committee to be vested at target due to the change in the issuer's business model. The remaining PSUs vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023.  One quarter of the initial PSUs were forfeited based on the failure of the issuer to achieve certain EBITDA milestones for the year ended December 31, 2021.  Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":3466,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1734},"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920111,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."}],"balance_after":3466,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1734},"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920110,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1010},"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920109,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance Stock Units","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":3030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The performance stock units (PSUs) vested upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs would have been forfeited. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The performance stock units (PSUs) vested upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs would have been forfeited. Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3030},"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920108,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"sale","planned":false,"acquired":false,"shares":1170,"price":3.6543,"value":4275.531,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $3.63 through $3.71, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth."}],"balance_after":12307,"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920107,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":13477,"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920106,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11743,"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920105,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10009,"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920104,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":3030,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8999,"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1998217,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-23T22:16:08.000Z","date":"2023-02-21","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on June 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on June 30, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on June 30, 2023."}],"balance_after":70000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-23-012287","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123012287/doc4.xml","form_type":"4"}},{"id":2021962,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-13T22:23:55.000Z","date":"2022-12-08","kind":"gift","acquired":false,"shares":716,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a charitable donation."}],"balance_after":5969,"source":{"system":"sec-edgar","filing":"0001209191-23-008817","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123008817/doc5.xml","form_type":"5"}},{"id":2091815,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Unit","published_at":"2022-12-10T00:38:31.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024."}],"balance_after":770,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":388},"source":{"system":"sec-edgar","filing":"0001209191-22-060587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060587/doc4.xml","form_type":"4"}},{"id":2091814,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Unit","published_at":"2022-12-10T00:38:31.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":1156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024."}],"balance_after":2311,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1156},"source":{"system":"sec-edgar","filing":"0001209191-22-060587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060587/doc4.xml","form_type":"4"}},{"id":2091813,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Unit","published_at":"2022-12-10T00:38:31.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest in three equal installments annually, becoming fully vested on March 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest in three equal installments annually, becoming fully vested on March 30, 2023."}],"balance_after":1010,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1010},"source":{"system":"sec-edgar","filing":"0001209191-22-060587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060587/doc4.xml","form_type":"4"}},{"id":2091812,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-12-10T00:38:31.000Z","date":"2022-12-06","kind":"sale","acquired":false,"shares":1048,"price":4.9475,"value":5184.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $4.66 through $5.41, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth."}],"balance_after":6685,"source":{"system":"sec-edgar","filing":"0001209191-22-060587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060587/doc4.xml","form_type":"4"}},{"id":2091811,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-12-10T00:38:31.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":7733,"source":{"system":"sec-edgar","filing":"0001209191-22-060587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060587/doc4.xml","form_type":"4"}},{"id":2091810,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-12-10T00:38:31.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":1156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":7345,"source":{"system":"sec-edgar","filing":"0001209191-22-060587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060587/doc4.xml","form_type":"4"}},{"id":2091809,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-12-10T00:38:31.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":6189,"source":{"system":"sec-edgar","filing":"0001209191-22-060587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060587/doc4.xml","form_type":"4"}},{"id":2313734,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Performance Stock Units","published_at":"2022-03-31T21:16:11.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The performance stock units (\"PSUs\") vest on April 5, 2025 based the total shareholder return (\"TSR\") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The performance stock units (\"PSUs\") vest on April 5, 2025 based the total shareholder return (\"TSR\") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The performance stock units (\"PSUs\") vest on April 5, 2025 based the total shareholder return (\"TSR\") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":260000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001209191-22-021795","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122021795/doc4.xml","form_type":"4"}},{"id":2317373,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2022-03-28T11:00:16.000Z","date":"2022-03-23","kind":"grant","acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."}],"balance_after":260000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001209191-22-021210","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122021210/doc4.xml","form_type":"4"}},{"id":2317372,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2022-03-28T11:00:10.000Z","date":"2022-03-23","kind":"grant","acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."}],"balance_after":260000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001209191-22-021208","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122021208/doc4.xml","form_type":"4"}},{"id":2334614,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2022-03-15T11:00:15.000Z","date":"2022-03-14","kind":"exercise","acquired":false,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 14, 2022, the reporting person received 230,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on December 13, 2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested on December 13, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested on December 13, 2021."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001209191-22-018682","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122018682/doc4.xml","form_type":"4"}},{"id":2334613,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-03-15T11:00:15.000Z","date":"2022-03-14","kind":"exercise","acquired":true,"shares":230000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 14, 2022, the reporting person received 230,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on December 13, 2021."}],"balance_after":258908,"source":{"system":"sec-edgar","filing":"0001209191-22-018682","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122018682/doc4.xml","form_type":"4"}},{"id":2555520,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-10-01T21:00:55.000Z","date":"2021-09-29","kind":"other","acquired":false,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"shares","element":"transactionShares","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Underlying shares were subject to vesting as follows: 40,000 shares on the first anniversary date of the grant, 40,000 shares on the second anniversary date of the grant, and 40,000 shares on the third anniversary date of the grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Underlying shares were subject to vesting as follows: 40,000 shares on the first anniversary date of the grant, 40,000 shares on the second anniversary date of the grant, and 40,000 shares on the third anniversary date of the grant."}],"balance_after":0,"derivative":{"exercise_price":5.16,"exercise_date":"2019-03-15","expiration_date":"2028-03-15","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001209191-21-058493","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121058493/doc4.xml","form_type":"4"}},{"id":2555519,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-10-01T21:00:55.000Z","date":"2021-09-29","kind":"other","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"shares","element":"transactionShares","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Underlying shares were subject to vesting as follows: 8,333 shares on the first anniversary date of the grant, 8,333 shares on the second anniversary date of the grant, and 8,334 shares on the third anniversary date of the grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Underlying shares were subject to vesting as follows: 8,333 shares on the first anniversary date of the grant, 8,333 shares on the second anniversary date of the grant, and 8,334 shares on the third anniversary date of the grant."}],"balance_after":0,"derivative":{"exercise_price":6.83,"exercise_date":"2018-03-15","expiration_date":"2027-03-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-058493","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121058493/doc4.xml","form_type":"4"}},{"id":2555518,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-10-01T21:00:55.000Z","date":"2021-09-29","kind":"other","acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"shares","element":"transactionShares","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Underlying shares were subject to vesting as follows: 50,000 shares on the first anniversary date of the grant, 50,000 shares on the second anniversary date of the grant, and 50,000 shares on the third anniversary date of the grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Underlying shares were subject to vesting as follows: 50,000 shares on the first anniversary date of the grant, 50,000 shares on the second anniversary date of the grant, and 50,000 shares on the third anniversary date of the grant."}],"balance_after":0,"derivative":{"exercise_price":6.26,"exercise_date":"2017-09-22","expiration_date":"2026-09-22","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-21-058493","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121058493/doc4.xml","form_type":"4"}},{"id":2555517,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-10-01T21:00:55.000Z","date":"2021-09-29","kind":"other","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"shares","element":"transactionShares","label":"F3","text":"Stock options exchanged for RSUs pursuant to the Option Exchange Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Underlying shares were subject to vesting as follows: 50,000 shares on the first anniversary date of the grant, and 50,000 shares on the second anniversary date of the grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Underlying shares were subject to vesting as follows: 50,000 shares on the first anniversary date of the grant, and 50,000 shares on the second anniversary date of the grant."}],"balance_after":0,"derivative":{"exercise_price":7.72,"exercise_date":"2016-06-04","expiration_date":"2025-06-04","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-21-058493","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121058493/doc4.xml","form_type":"4"}},{"id":2555516,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2021-10-01T21:00:55.000Z","date":"2021-09-29","kind":"grant","acquired":true,"shares":57797,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units (RSUs) issued pursuant to the Issuer's stock option exchange program approved by stockholders at the Issuer's 2021 annual meeting (the \"Option Exchange Program\"). Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024."}],"balance_after":57797,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":57797},"source":{"system":"sec-edgar","filing":"0001209191-21-058493","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919121058493/doc4.xml","form_type":"4"}},{"id":2646980,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2021-07-02T21:48:12.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":173333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024."}],"balance_after":173333,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":173333},"source":{"system":"sec-edgar","filing":"0001387131-21-007117","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121007117/ownership.xml","form_type":"4"}},{"id":2646979,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Performance Stock Units","published_at":"2021-07-02T21:48:12.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":346667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":346667,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":346667},"source":{"system":"sec-edgar","filing":"0001387131-21-007117","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121007117/ownership.xml","form_type":"4"}},{"id":2717897,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2021-05-13T00:43:21.000Z","date":"2021-05-10","kind":"exercise","acquired":false,"shares":50500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 10, 2021, the reporting person received 50,500 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021."},{"field":"shares","element":"transactionShares","label":"F4","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement."}],"balance_after":101000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":50500},"source":{"system":"sec-edgar","filing":"0001387131-21-005570","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121005570/ownership.xml","form_type":"4"}},{"id":2717896,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2021-05-13T00:43:21.000Z","date":"2021-05-11","kind":"sale","acquired":false,"shares":21592,"price":1.04,"value":22455.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $1.03 to $1.06 for an average weighted sale price of $1.04. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":28908,"source":{"system":"sec-edgar","filing":"0001387131-21-005570","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121005570/ownership.xml","form_type":"4"}},{"id":2717895,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2021-05-13T00:43:21.000Z","date":"2021-05-10","kind":"exercise","acquired":true,"shares":50500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 10, 2021, the reporting person received 50,500 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021."}],"balance_after":50500,"source":{"system":"sec-edgar","filing":"0001387131-21-005570","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121005570/ownership.xml","form_type":"4"}}]}